NCT00135967

Mycophenolate Mofetil in Membranous Nephropathy

Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 30 (planned)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects. In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.

Conditions

• Glomerulonephritis, Membranous

Interventions

Type	Name	Description
DRUG	mycophenolate mofetil orally 1000 mg twice a day (BID)
DRUG	prednisone 0,5 mg/kg orally on alternate days
DRUG	intravenous (i.v.) methylprednisolone 1000 mg, total 9

Timeline

• Start date: 2002-05-01
• First posted: 2005-08-26
• Last updated: 2005-12-06

Locations

1 site across 1 country: Netherlands